99mTc-MIBI whole body scintigraphy and P-glycoprotein for the prediction of multiple drug resistance in multiple myeloma patients

Babak Fallahi, Davood Beiki, Seyed Asadollah Mousavi, Ali Gholamrezanezhad, Mohammad Eftekhari, Armaghan Fard-Esfahani, Kamran Alimoghaddam, Sahar Mirpour, Alireza Eskandarian, Mohsen Saghari

Research output: Contribution to journalArticle

Abstract

Multi-drug resistance (MDR) is a major challenge in the treatment of multiple myeloma (MM). There is low sensitivity of technetium-99m methoxy isobutyl isonitrile (99mTc-MIBI) whole body scan (WBS) in the detection of active MM lesions, because 99Tc-MIBI is washed out from malignant cells in the presence of P-glycoprotein (PGP). The objective of the present cohort study was to evaluate of 99mTc-MIBI WBS in the prediction of MDR in MM patients during a course of one year follow up. Thirty four patients with MM (25 male, 9 female of mean age 54.12±11.46 years) entered the study. Thirteen patients had no previous history of treatment and 21 had a history of previous chemo-radiotherapy. The diagnosis and staging of the disease were based upon routine laboratory and clinical criteria like bone marrow plasma cell count, serum M component, calcium, albumin, β2- microglobulin. Measurements of PGP and WBS using 99mTc-MIBI were performed before initialization of treatment and the response to treatment was assessed one year later. The baseline 99mTc-MIBI WBS were considered positive for the detection of active lesions when at least one area of non-physiologic increased activity was noted. The follow up 99mTc- MIBI WBS was positive for MDR when the patient had active disease but normal WBS. Our results showed that for WBS, the sensitivity, specificity, positive predictive value, negative predictive value and accuracy in active state for the diagnosis of MDR were 38.9%, 62.5%, 70%, 31.2% and 46.1%, respectively. Also the above values for the detection of MDR, using PGP values were 50%, 50%, 69.2%, 30.8% and 50%, respectively. The relative risk of resistant to multiple regimens of chemotherapy after one year follow up in patients with negative to patients with positive 99mTc-MIBI WBS was 1.02 (0.60-1.72). In conclusion, we found a low sensitivity of WBS and of PGP in the detection of MDR in patients with active MM. However, both WBS and PGP have 70% and 69% positive predictive value for MDR.

Original languageEnglish (US)
JournalHellenic Journal of Nuclear Medicine
Volume12
Issue number3
StatePublished - Sep 1 2009
Externally publishedYes

Fingerprint

Whole Body Imaging
Multiple Drug Resistance
P-Glycoprotein
Multiple Myeloma
Radionuclide Imaging
Myeloma Proteins
Technetium
Therapeutics
Plasma Cells
Bone Marrow Cells
Albumins
Cohort Studies
Radiotherapy
Cell Count
Calcium

Keywords

  • Tc-sestamibi
  • Multi-drug resistance
  • Multiple myeloma
  • P-glycoprotein
  • Scintigraphy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Fallahi, B., Beiki, D., Mousavi, S. A., Gholamrezanezhad, A., Eftekhari, M., Fard-Esfahani, A., ... Saghari, M. (2009). 99mTc-MIBI whole body scintigraphy and P-glycoprotein for the prediction of multiple drug resistance in multiple myeloma patients. Hellenic Journal of Nuclear Medicine, 12(3).

99mTc-MIBI whole body scintigraphy and P-glycoprotein for the prediction of multiple drug resistance in multiple myeloma patients. / Fallahi, Babak; Beiki, Davood; Mousavi, Seyed Asadollah; Gholamrezanezhad, Ali; Eftekhari, Mohammad; Fard-Esfahani, Armaghan; Alimoghaddam, Kamran; Mirpour, Sahar; Eskandarian, Alireza; Saghari, Mohsen.

In: Hellenic Journal of Nuclear Medicine, Vol. 12, No. 3, 01.09.2009.

Research output: Contribution to journalArticle

Fallahi, B, Beiki, D, Mousavi, SA, Gholamrezanezhad, A, Eftekhari, M, Fard-Esfahani, A, Alimoghaddam, K, Mirpour, S, Eskandarian, A & Saghari, M 2009, '99mTc-MIBI whole body scintigraphy and P-glycoprotein for the prediction of multiple drug resistance in multiple myeloma patients', Hellenic Journal of Nuclear Medicine, vol. 12, no. 3.
Fallahi, Babak ; Beiki, Davood ; Mousavi, Seyed Asadollah ; Gholamrezanezhad, Ali ; Eftekhari, Mohammad ; Fard-Esfahani, Armaghan ; Alimoghaddam, Kamran ; Mirpour, Sahar ; Eskandarian, Alireza ; Saghari, Mohsen. / 99mTc-MIBI whole body scintigraphy and P-glycoprotein for the prediction of multiple drug resistance in multiple myeloma patients. In: Hellenic Journal of Nuclear Medicine. 2009 ; Vol. 12, No. 3.
@article{4adadf092a1c4b40bf56f7092fc0af0f,
title = "99mTc-MIBI whole body scintigraphy and P-glycoprotein for the prediction of multiple drug resistance in multiple myeloma patients",
abstract = "Multi-drug resistance (MDR) is a major challenge in the treatment of multiple myeloma (MM). There is low sensitivity of technetium-99m methoxy isobutyl isonitrile (99mTc-MIBI) whole body scan (WBS) in the detection of active MM lesions, because 99Tc-MIBI is washed out from malignant cells in the presence of P-glycoprotein (PGP). The objective of the present cohort study was to evaluate of 99mTc-MIBI WBS in the prediction of MDR in MM patients during a course of one year follow up. Thirty four patients with MM (25 male, 9 female of mean age 54.12±11.46 years) entered the study. Thirteen patients had no previous history of treatment and 21 had a history of previous chemo-radiotherapy. The diagnosis and staging of the disease were based upon routine laboratory and clinical criteria like bone marrow plasma cell count, serum M component, calcium, albumin, β2- microglobulin. Measurements of PGP and WBS using 99mTc-MIBI were performed before initialization of treatment and the response to treatment was assessed one year later. The baseline 99mTc-MIBI WBS were considered positive for the detection of active lesions when at least one area of non-physiologic increased activity was noted. The follow up 99mTc- MIBI WBS was positive for MDR when the patient had active disease but normal WBS. Our results showed that for WBS, the sensitivity, specificity, positive predictive value, negative predictive value and accuracy in active state for the diagnosis of MDR were 38.9{\%}, 62.5{\%}, 70{\%}, 31.2{\%} and 46.1{\%}, respectively. Also the above values for the detection of MDR, using PGP values were 50{\%}, 50{\%}, 69.2{\%}, 30.8{\%} and 50{\%}, respectively. The relative risk of resistant to multiple regimens of chemotherapy after one year follow up in patients with negative to patients with positive 99mTc-MIBI WBS was 1.02 (0.60-1.72). In conclusion, we found a low sensitivity of WBS and of PGP in the detection of MDR in patients with active MM. However, both WBS and PGP have 70{\%} and 69{\%} positive predictive value for MDR.",
keywords = "Tc-sestamibi, Multi-drug resistance, Multiple myeloma, P-glycoprotein, Scintigraphy",
author = "Babak Fallahi and Davood Beiki and Mousavi, {Seyed Asadollah} and Ali Gholamrezanezhad and Mohammad Eftekhari and Armaghan Fard-Esfahani and Kamran Alimoghaddam and Sahar Mirpour and Alireza Eskandarian and Mohsen Saghari",
year = "2009",
month = "9",
day = "1",
language = "English (US)",
volume = "12",
journal = "Hellenic Journal of Nuclear Medicine",
issn = "1790-5427",
publisher = "Hellenic Society of Nuclear Medicine",
number = "3",

}

TY - JOUR

T1 - 99mTc-MIBI whole body scintigraphy and P-glycoprotein for the prediction of multiple drug resistance in multiple myeloma patients

AU - Fallahi, Babak

AU - Beiki, Davood

AU - Mousavi, Seyed Asadollah

AU - Gholamrezanezhad, Ali

AU - Eftekhari, Mohammad

AU - Fard-Esfahani, Armaghan

AU - Alimoghaddam, Kamran

AU - Mirpour, Sahar

AU - Eskandarian, Alireza

AU - Saghari, Mohsen

PY - 2009/9/1

Y1 - 2009/9/1

N2 - Multi-drug resistance (MDR) is a major challenge in the treatment of multiple myeloma (MM). There is low sensitivity of technetium-99m methoxy isobutyl isonitrile (99mTc-MIBI) whole body scan (WBS) in the detection of active MM lesions, because 99Tc-MIBI is washed out from malignant cells in the presence of P-glycoprotein (PGP). The objective of the present cohort study was to evaluate of 99mTc-MIBI WBS in the prediction of MDR in MM patients during a course of one year follow up. Thirty four patients with MM (25 male, 9 female of mean age 54.12±11.46 years) entered the study. Thirteen patients had no previous history of treatment and 21 had a history of previous chemo-radiotherapy. The diagnosis and staging of the disease were based upon routine laboratory and clinical criteria like bone marrow plasma cell count, serum M component, calcium, albumin, β2- microglobulin. Measurements of PGP and WBS using 99mTc-MIBI were performed before initialization of treatment and the response to treatment was assessed one year later. The baseline 99mTc-MIBI WBS were considered positive for the detection of active lesions when at least one area of non-physiologic increased activity was noted. The follow up 99mTc- MIBI WBS was positive for MDR when the patient had active disease but normal WBS. Our results showed that for WBS, the sensitivity, specificity, positive predictive value, negative predictive value and accuracy in active state for the diagnosis of MDR were 38.9%, 62.5%, 70%, 31.2% and 46.1%, respectively. Also the above values for the detection of MDR, using PGP values were 50%, 50%, 69.2%, 30.8% and 50%, respectively. The relative risk of resistant to multiple regimens of chemotherapy after one year follow up in patients with negative to patients with positive 99mTc-MIBI WBS was 1.02 (0.60-1.72). In conclusion, we found a low sensitivity of WBS and of PGP in the detection of MDR in patients with active MM. However, both WBS and PGP have 70% and 69% positive predictive value for MDR.

AB - Multi-drug resistance (MDR) is a major challenge in the treatment of multiple myeloma (MM). There is low sensitivity of technetium-99m methoxy isobutyl isonitrile (99mTc-MIBI) whole body scan (WBS) in the detection of active MM lesions, because 99Tc-MIBI is washed out from malignant cells in the presence of P-glycoprotein (PGP). The objective of the present cohort study was to evaluate of 99mTc-MIBI WBS in the prediction of MDR in MM patients during a course of one year follow up. Thirty four patients with MM (25 male, 9 female of mean age 54.12±11.46 years) entered the study. Thirteen patients had no previous history of treatment and 21 had a history of previous chemo-radiotherapy. The diagnosis and staging of the disease were based upon routine laboratory and clinical criteria like bone marrow plasma cell count, serum M component, calcium, albumin, β2- microglobulin. Measurements of PGP and WBS using 99mTc-MIBI were performed before initialization of treatment and the response to treatment was assessed one year later. The baseline 99mTc-MIBI WBS were considered positive for the detection of active lesions when at least one area of non-physiologic increased activity was noted. The follow up 99mTc- MIBI WBS was positive for MDR when the patient had active disease but normal WBS. Our results showed that for WBS, the sensitivity, specificity, positive predictive value, negative predictive value and accuracy in active state for the diagnosis of MDR were 38.9%, 62.5%, 70%, 31.2% and 46.1%, respectively. Also the above values for the detection of MDR, using PGP values were 50%, 50%, 69.2%, 30.8% and 50%, respectively. The relative risk of resistant to multiple regimens of chemotherapy after one year follow up in patients with negative to patients with positive 99mTc-MIBI WBS was 1.02 (0.60-1.72). In conclusion, we found a low sensitivity of WBS and of PGP in the detection of MDR in patients with active MM. However, both WBS and PGP have 70% and 69% positive predictive value for MDR.

KW - Tc-sestamibi

KW - Multi-drug resistance

KW - Multiple myeloma

KW - P-glycoprotein

KW - Scintigraphy

UR - http://www.scopus.com/inward/record.url?scp=72249102180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72249102180&partnerID=8YFLogxK

M3 - Article

C2 - 19936339

AN - SCOPUS:72249102180

VL - 12

JO - Hellenic Journal of Nuclear Medicine

JF - Hellenic Journal of Nuclear Medicine

SN - 1790-5427

IS - 3

ER -